. . . "1"^^ . . "1"^^ . " chronic myelogeneous leukemia" . "0"^^ . . "1"^^ . "2010-04-16+02:00"^^ . "Studium diverzity exprese miRNA u chronick\u00E9 myeloidn\u00ED leuk\u00E9mie" . "2008-01-01+01:00"^^ . "miRNA" . "http://www.isvav.cz/projectDetail.do?rowId=GP301/08/P154"^^ . . "miRNA; chronic myelogeneous leukemia; bioarray; Real-Time PCR"@en . . . . . "2010-12-31+01:00"^^ . " bioarray" . "2015-03-20+01:00"^^ . "Chronic myelogeneous leukemia (CML) is a malignant disorder caused by abnormal function of fusion protein BCR-ABL as the consequence of reciprocal translocation t(9;22) (q34;q11). A great progress in CML treatment was achieved by tyrosine kinase inhibitor, imatinib. However, the resistance or suboptimal response to treatment appeared in some patients. CML is clinically heterogeneous disorder. The molecular basis for this clinical heterogeneity is unclear. MiRNAs are small non-coding RNA regulating gene expression. During cell development and differentiation, miRNA is tightly regulated in tissue specific manner. Aberrant expression of specific miRNAs has recently been described mainly for chronic lymphocytic leukemia (CLL). The aim of the proposed project is to reveal specific miRNAs, which contribute to pathogenesis and heterogeneity of CML."@en . . . . "The miRNA expression diversity study in chronic myelogeneous leukemia"@en . "GP301/08/P154" . . . . . "Chronick\u00E1 myeloidn\u00ED leuk\u00E9mie (CML) je malign\u00ED onemocn\u011Bn\u00ED krvetvorby, je\u017E je d\u016Fsledkem recipro\u010Dn\u00ED translokace t(9;22) (q34;q11) za vzniku f\u00FAzn\u00EDho proteinu BCR-ABL s\u00A0abnorm\u00E1ln\u00ED funkc\u00ED. Velk\u00E9ho pokroku v\u00A0l\u00E9\u010Db\u011B CML bylo doc\u00EDleno pomoc\u00ED inhibitoru tyrozin kin\u00E1z, imatinibu. Av\u0161ak u nemal\u00E9 skupiny pacient\u016F se objevuje probl\u00E9m spjat\u00FD s\u00A0rezistenc\u00ED nebo suboptim\u00E1ln\u00ED odpov\u011Bd\u00ED na l\u00E9\u010Dbu. Klinick\u00FD pr\u016Fb\u011Bh onemocn\u011Bn\u00ED a citlivost v\u016F\u010Di l\u00E9\u010Db\u011B je velice heterogenn\u00ED. Molekul\u00E1rn\u00ED podstata t\u00E9to heterogenity nen\u00ED st\u00E1le objasn\u011Bna. MiRNA jsou mal\u00E9 nek\u00F3duj\u00EDc\u00ED RNA, jen\u017E posttranskrip\u010Dn\u011B reguluj\u00ED genovou expresi. B\u011Bhem bun\u011B\u010Dn\u00E9ho v\u00FDvoje a diferenciace je exprese miRNA tk\u00E1\u0148ov\u011B specificky regulov\u00E1na. Aberantn\u00ED exprese specifick\u00FDch miRNA byla zji\u0161t\u011Bna a zat\u00EDm nejv\u00EDce prob\u00E1d\u00E1na u chronick\u00E9 lymfocyt\u00E1rn\u00ED leuk\u00E9mie (CLL). C\u00EDlem p\u0159edkl\u00E1dan\u00E9ho projektu je nal\u00E9zt specifick\u00E9 miRNA, kter\u00E9 mohou ovliv\u0148ovat pr\u016Fb\u011Bh onemocn\u011Bn\u00ED CML a odpov\u011B\u010F na l\u00E9\u010Dbu a tak p\u0159isp\u00EDvat\u00A0ji\u017E k v\u00FD\u0161e zmi\u0148ovan\u00E9 heterogenit\u011B." . . "0"^^ . "V dob\u011B n\u00E1vrhu projektu (r. 2007) byla zn\u00E1ma pouze jedin\u00E1 pr\u00E1ce v souvislosti s hled\u00E1n\u00EDm specifick\u00FDch microRNA, kter\u00E9 mohou souviset s chronickou myeloidn\u00ED leuk\u00E9mi\u00ED [Venturini L et al.: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007, 109:4399-405]. Ned\u00E1vno se na tomto poli objevily dal\u0161\u00ED 4 pr\u00E1ce, kter\u00E9 popisujeme v \u010D\u00E1sti a"@cs . "To our best knowledge only one publication was known about microRNA associated with CML at the time of the project proposal [Venturini L, et al.: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007, 109:4399-405.]. Recently, other four works appeared and we discuss them in the part a) of the final report of this project. This project brought"@en .